Pfizer faces several headwinds, including patent cliffs, regulatory risks, and a setback in obesity drug development. Click ...

Although the immediate market response was negative, most pharmaceutical stocks recovered after Wall Street analysts ...

Pharmaceutical stocks, including Pfizer (NYSE: PFE ... rebounded after Wall Street analysts highlighted the significant legal challenges the order would face. The pharmaceutical industry has ...

The legal challenge carries a risk as well, as it could cupper the development of Enanta's drug – and possibly Pardes' – if Pfizer can prove it was the first to develop a drug candidate ...

In a landmark decision that challenges the European Commission’s transparency standards, the General Court of the European ...

According to InvestingPro data, the company faces significant financial challenges ... ITIL agreed to cover a transaction fee and Pfizer’s legal expenses. Iterum’s CEO, Corey Fishman ...

COVID shots should target newer strains of JN.1 variant in 2025-26 campaign, US FDA advisers say U.S. Food and Drug Administration advisers unanimously recommended on Thursday that COVID-19 ...

Global pharmaceutical shares jumped in intraday trading Monday, reversing their pre-market declines, as investors anticipated ...

Pfizer Inc (NYSE:PFE) experienced a 6% operational revenue decline in Q1 2025, largely due to lower Paxlovid revenues and changes in Medicare Part D design. The company faces challenges from ...

In this article, we are going to take a look at where Pfizer Inc. (NYSE ... These frameworks provide patients and developers with legal protection by simplifying liability standards for flawed ...

The pressure to strategize on its pipeline comes as Pfizer prepares for new challenges. The company is bracing for a more than $15 billion loss over the next decade as patents for six major drugs ...